摘要
目的 探讨注射用丹参多酚酸治疗急性脑梗塞的效果及对认知功能、同型半胱氨酸(Hcy)、神经元特异性烯醇化酶(NSE)、S-100β、胶质纤维酸性蛋白(GFAP)的影响.方法 选取唐山市人民医院2017年10月-2018年10月收治的急性脑梗塞患者162例,采用随机数字表法分为两组(各81例),对照组实施常规治疗,观察者在常规治疗基础上联用注射用丹参多酚酸100mg/次,静脉滴注,1次/d,连续治疗14d,于治疗前后检测Hcy、NSE、S-100β和GFAP,并评定患者认知功能、神经功能,比较两组临床疗效及不良反应.结果 两组患者治疗后Hcy、NSE、S-100β、GFAP、美国国立卫生研究院卒中量表(NHISS)评分均较治疗前降低(P<0.05),简易精神状态评价量表(MMSE)评分、蒙特利尔认知评估量表(MOCA)评分较治疗前增加(P<0.05);且观察组患者治疗后Hey、NSE、S-100β、GFAP、NHISS评分低于对照组(P<0.05),治疗后MMSE评分、MOCA评分高于对照组(P<0.05).观察组患者总有效率高于对照组(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05).结论 注射用丹参多酚酸治疗急性脑梗塞的效果显著,可改善认知功能和神经功能状况,并改善Hcy、NSE、S-100β、GFAP等指征.
Objective To investigate the effect of Salvianolic Acids for Injection(SAFI)in treatment for acute cerebral infarction and its influence on cognitive function,homocysteine(Hcy),neuron specific enolase(NSE),S-1OOβ,and glial fibrillary acidic protein(GFAP).Methods A total of 162 patients were selected in Tangshan People's Hospital from October 2017 to October 2018,who were divided into two groups by random number table method(n=81).81 patients in the observation group received routine treatment as control group.81 patients combined with SAFI 100 mg/time,intravenous drip,once a day,continuous treatment for 14 days.Hcy,NSE,S-100β,and GFAP were detected before and after treatment,and cognitive function and neurological function were assessed.Clinical efficacy and adverse reactions were compared between two groups.Results After the treatment,Hcy,NSE,S-100β,GFAP,and NHISS score were decreased in two groups(P<0.05).MMSE score and MOCA score were increased in two groups(P<0.05).Hcy,NSE,S-100β,GFAP,and NHISS score in observation group were lower than control group(P<0.05).MMSE score and MOCA score in observation group were higher than control group(P<0.05).Total effective rate in observation group was higher than control group(P<0.05).There were no significant differences in adverse reactions between two groups(P>0.05).Conclusion SAFI has significant effect in treatment for acute cerebral infarction,which can improve cognitive function and neurological function,and improve indicators of Hcy,NSE,S-100β,and GFAP.
作者
董晓柳
崔璐莎
王增英
赵蕊
刘海艳
张秀清
佟玲
DONG Xiaoliu;CUI Lusha;WANG Zengying;ZHAO Rui;LIU Haiyan;ZHANG Xiuqing;TONG Ling(Department of Neurological Rehabilitation,Tangshan People's Hospital,Tangshan 063001,China;Kailuan Mental Health Center,Tangshan 063000,China;RehabilitationHospital of Kailuan General Hospital,Tangshan 063000,China;Pharmacy Department,Tangshan People's Hospital,Tangshan 063001,China)
出处
《药物评价研究》
CAS
2019年第11期2253-2256,共4页
Drug Evaluation Research
基金
河北省医学科学研究重点课题(20171288,20181217)
